HR2623119th CongressWALLET

Innovative Therapies Centers of Excellence Act of 2025

Sponsored By: Representative Correa

In Committee

Summary

Creates a network of at least five VA "innovative therapies centers of excellence" to research, train clinicians, and deliver psychedelic and other novel treatments for specified conditions. This law builds a geographically distributed system that links clinical care, research, and education around therapies like psilocybin, ketamine, MDMA, and others designated by the VA.

Your PRIA Score

Score Hidden

Personalized for You

How does this bill affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Bill Overview

Analyzed Economic Effects

2 provisions identified: 2 benefits, 0 costs, 0 mixed.

Funding and expert review for VA centers

The bill would authorize $30 million each year for research and education at these centers. Congress would still need to appropriate the money, and the VA health leader could move some existing medical and research funds to help the centers. The VA would set up a panel of innovative‑therapy experts to score site proposals and advise the VA health leader. Half the members would serve three‑year terms and half two‑year terms. The panel would not be subject to chapter 10 of title 5. The VA would report to Congress each year on the centers’ activities and findings.

New VA centers for innovative therapies

If enacted, VA would pick at least five medical centers as Innovative Therapies Centers of Excellence. Centers would open only if Congress provides money. Sites would be chosen after expert peer review. Each site would need ties to accredited medical, psychiatry, and social work schools, with training for residents. The centers would target PTSD, depression, anxiety, chronic pain, Parkinson's, and substance use. Therapies could include MDMA, psilocybin, ketamine, 5‑MeO‑DMT, and ibogaine, and the VA could add more. VA would spread centers across regions, coordinate care and research, build provider networks, keep a national data repository, and include a veterans advisory group.

Sponsors & CoSponsors

Sponsor

Correa

CA • D

Cosponsors

  • Bergman

    MI • R

    Sponsored 4/3/2025

  • Crenshaw

    TX • R

    Sponsored 4/3/2025

  • Khanna

    CA • D

    Sponsored 4/3/2025

  • Luttrell

    TX • R

    Sponsored 4/3/2025

  • Swalwell

    CA • D

    Sponsored 4/7/2025

  • Lee (NV)

    NV • D

    Sponsored 4/7/2025

  • Elfreth

    MD • D

    Sponsored 5/5/2025

  • Wied

    WI • R

    Sponsored 5/6/2025

  • Budzinski

    IL • D

    Sponsored 6/30/2025

  • Barrett

    MI • R

    Sponsored 7/10/2025

  • Schrier

    WA • D

    Sponsored 7/25/2025

  • Fields

    LA • D

    Sponsored 9/10/2025

  • Van Drew

    NJ • R

    Sponsored 9/11/2025

  • Pfluger

    TX • R

    Sponsored 9/23/2025

  • Suozzi

    NY • D

    Sponsored 9/26/2025

  • Fitzpatrick

    PA • R

    Sponsored 10/3/2025

  • Thompson (MS)

    MS • D

    Sponsored 10/3/2025

  • Thompson (CA)

    CA • D

    Sponsored 11/4/2025

  • Lofgren

    CA • D

    Sponsored 11/17/2025

  • Barr

    KY • R

    Sponsored 11/17/2025

  • Ruiz

    CA • D

    Sponsored 12/1/2025

  • Lawler

    NY • R

    Sponsored 1/6/2026

  • Massie

    KY • R

    Sponsored 2/25/2026

  • Del. Radewagen, Aumua Amata Coleman [R-AS-At Large]

    AS • R

    Sponsored 3/16/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in